11 November 2014: Clinical Research
Ophthalmological Features of Parkinson Disease
Barbara Nowacka ABCDEFG , Wojciech Lubinski ABDEFG , Krystyna Honczarenko AB , Andrzej Potemkowski AB , Krzysztof Safranow CD
DOI: 10.12659/MSM.890861
Med Sci Monit 2014; 20:2243-2249
Abstract
BACKGROUND: The aim of this study was to determine the type and frequency of ophthalmologic changes occurring in patients with Parkinson disease (PD).
MATERIAL AND METHODS: One hundred consecutive patients (196 eyes) with idiopathic PD and a control group consisting of 100 healthy patients (196 eyes) matched for age and sex underwent a complete ophthalmological examination of both eyes, including assessment of patient medical history, dry eye questionare, and visual hallucinations questionnaire, distance and near best corrected visual acuity (DBCVA, NBCVA), color vision, distance photopic contrast sensitivity, near point of convergence, slit lamp examination of the eye anterior segment, tear film osmolarity and breakup time, aqueous tear production, and intraocular pressure, as well as fundus examination and evaluation of the perimacular retinal thickness (RT) and peripapillary retinal nerve fiber layer (RNFL) thickness.
RESULTS: In the eyes of PD patients DBCVA, NBCVA, contrast sensitivity, and color discrimination were significantly reduced. We also detected increased frequency of convergence insufficiency, seborrhoic blepharitis, meibomian gland disease (MGD), dry eye syndrome, nuclear and posterior subcapsular cataract, and glaucoma (p<0.05). However, intraocular pressure (IOP) was significantly lower in the PD group compared to controls. The frequency of visual hallucinations, age-related macular degeneration (ARMD), and other ophthalmological diseases, as well as RT and RNFL thickness, did not significantly differ between investigated groups.
CONCLUSIONS: Clinicians need to be aware of the association between PD and ophthalmological changes. Restoration of good-quality vision has a great impact on PD patients’ quality of life, reduction of costs of treatment and care, and rehabilitation.
Keywords: Eye - pathology, Case-Control Studies, Glaucoma - pathology, Parkinson Disease - pathology, Questionnaires
Background
Parkinson disease (PD), one of the most common neurodegenerative disorders, is characterized by progressive dopamine depletion due to dopaminergic neuron death in the substantia nigra. Visual pathway changes are also observed. In the eye, dopamine is contained in the subtype of amacrine cells A18 in the inner plexiform layer of the retina [1], while dopaminergic receptors are spread across the whole retina. The problem of ocular diseases associated with PD is not well known. It has been suggested that PD patients should be considered at increased risk of having dry eye problems [2–5], primary open-angle glaucoma [6], visual hallucinations [7–9], difficulties in oculomotor control [10,11], and deficits in contrast sensitivity and color discrimination [12–15], but, according to the WHO, there are no data about the 2 most frequent causes of blindness in the elderly, according to the WHO – cataract and age-related macular degeneration (ARMD). WHO data are cataract and ARMD, not their the frequency in PD patients.
Material and Methods
PATIENTS:
We enrolled 100 consecutive patients (196 eyes) aged 68.5±10.2 years with idiopathic PD without dementia and a control group consisting of 100 healthy patients (196 eyes) matched for age and sex with mean age of 68.6±9.8 years (p=0.95). For evaluation of RT, RNFL thickness, color vision, and contrast sensitivity, 85 PD patients (164 eyes) aged 67.4±10.3 years and 85 controls (164 eyes) aged 67.6±10.0 years, all without glaucoma, were recruited (p=0.91). We excluded all individuals with any systemic diseases, taking medications known to influence the organ of vision, or who had previous ocular surgery other than uneventful phacoemulsification. Patients with diagnosed idiopathic PD were referred for ophthalmological examination from the neurological outpatient clinics. The duration of PD and general medical history were recorded. PD staging was assessed with the modified Hoehn and Yahr (H-Y) scale. PD patients were examined in the morning without taking any antiparkinsonian drugs.
PROCEDURES:
Patients were interviewed to determine the presence and frequency of visual hallucinations and dry eye symptoms. To evaluate severity of dry eye disease, the Ocular Surface Disease Index (OSDI) questionnaire was used. To determine the distance and near best corrected visual acuity (DBCVA and NBCVA), the ETDRS logMAR chart and ETDRS near vision chart were used, respectively. A color vision examination (Farnsworth Dichotomous Test D-15) was performed separately for each eye, and contrast sensitivity (CSV-1000) was examined binocularly with and without high glare. Only subjects without glaucoma and best corrected visual acuity equal or better than 0.28 logMAR were enrolled to color vision and contrast sensitivity evaluation. The convergence insufficiency was recorded as positive when 1 or both eyes deviated out before the shown object reached 10 cm from the bridge of the nose. Examination of the anterior segment of the eye via slit-lamp biomicroscopy included evaluation of meibomian gland disease (MGD), intensity of lid-parallel conjunctival folds (LIPCOF), and presence of the other diseases. The severity of meibomian gland disease (MGD) was graded on the scale proposed by Bron et al. [16]: grade 0 – all glands clear of blockage; grade 1–1 or 2 capped (blocked) glands; grade 2–3 or 4 blocked glands with the secretions that appeared thick; grade 3 – approximately half of the glands blocked/stenosed; and grade 4 – more than half of the glands with viscous secretions. Degree of LIPCOF intensity was graded according to classification: degree 0 – no permanently present fold; degree 1 – single fold smaller than tear meniscus; degree 2 – single fold higher than tear meniscus; degree 3 – numerous folds not reaching the edges of the eyelids; and degree 4 – numerous folds reaching the edges of the eyelids. All tear film tests were performed before administration of any eye drops in the following order: non-invasive tear film break-up time (TBUT) (Tearscope), tear film osmolarity (TearLab Osmolarity System), and Shirmer’s test. Intraocular pressure was measured after topical anesthesia using a PASCAL Dynamic Contour Tonometer. Assessment of lens opacity (LOCS III scale), fundus examination, and Optical Coherence Tomography (OCT) scans (fast algorithms, time domain Stratus OCT, Carl Zeiss Meditec) were obtained in all participants after pupil dilation. The diagnosis of glaucoma was based on the presence of at least 1 of the following criteria: a characteristic repeatable pattern of glaucomatous visual field loss and a cup-to-disk ratio of 0.8 or greater, with an optic nerve head appearance consistent with glaucoma. All patients from the PD and control group with glaucoma were excluded from the retinal thickness (RT) and the retinal nerve fiber layer (RNFL) thickness comparison.
All subjects participating in this study gave written informed consent. The study was approved by Ethics Committee of the Pomeranian Medical University.
STATISTICAL ANALYSIS:
The results were compared using the Mann-Whitney U test for quantitative and rank variables, or using Fisher’s exact test for qualitative variables. A p-value <0.05 was considered significant. Quantitative data are presented as mean ± standard deviation (SD). Qualitative data are presented as percentages of eyes/patients and number of patients.
Results
Only 4 PD patients (4.0%) complained of visual hallucinations. There were no visual hallucinations in the control group (p=0.12). According to the dry eye assessment questionnaire, PD patients achieved significantly higher OSDI compared to controls (p<0.001). Patient characteristics and questionnaire results are shown in Table 1.
PD patients achieved significantly lower DBCVA than controls (0.15±0.23
In PD patients without glaucoma, DBCVA and NBCVA were significantly worse than those of controls without glaucoma (0.13±0.22
Discussion
Dopamine plays multiple roles in the eye. The results of previous studies indicate that it takes part in light adaptation [1,17], spatial contrast sensitivity, color discrimination [7,14,15], visuospatial problem solving, spatial working memory, oculomotor control [13], promotion of the photoreceptor renewal process, and reduction of its waste products accumulation [18], as well as probably being involved in the cyclic regulation of intraocular pressure [19]. Dopamine also seems to have an anti-apoptotic role [20]. According to our best knowledge, this is the first study to comprehensively describe ophthalmological changes in the course of PD.
PD causes visual dysfunction manifested by decreased visual acuity, contrast sensitivity, and color discrimination. Results of this study are consistent with previous research [12–14,21]. Poor visual function may be caused by lack of dopamine in the retina, abnormal eye movements, or poor blinking [22]. However, for the first time, we also observed significantly higher frequency of nuclear and posterior subcapsular cataract in the PD group, which may deteriorate visual functions. Oxidative stress has a great impact on cataract formation due to prevalent oxidation of lens DNA, proteins, and lipids [23]. One of the mechanisms in PD neurodegeneration is excessive oxidative stress, which may explain the higher frequency of cataract in PD patients. It is important to note that despite higher prevalence of cataract in the PD group, the frequency of pseudophakic eyes did not significantly differ between the 2 investigated groups, which suggests that PD patients are less frequently referred for cataract surgery. We also observed that PD patients more often had convergence insufficiency, which is consistent with previous studies [2,24]. This may lead to complaints of difficulties in reading, even with a restoration of normal near visual acuity.
In the literature, the prevalence of visual hallucinations in PD patients is estimated at up to 37% [7]. In this study, only 4 PD patients (4.0%) complained of visual hallucinations. There are many risk factors of visual hallucinations associated with PD, including cognitive impairment [12], decreased dopamine level before the next dose of levodopa, REM sleep dysfunction [25], longer disease duration and higher severity of disease, higher levodopa dosage and longer duration of treatment [26], impaired color discrimination and contrast sensitivity [27], and decreased visual acuity. In the present study, only patients without dementia were enrolled. Meanwhile, cognitive impairment seems to be one of the strongest risk factors for visual hallucinations [12]. Mean disease duration was quite short (5.6±4.8 years) and stage of PD according to the H-Y scale was relatively low (1.8±0.7). Although DBCVA was significantly worse in PD cases compared to controls, most of them had useful visual acuity. In summary, the PD patients who participated in this study did not have many risk factors for development of visual hallucinations, which may explain their low frequency.
Results of this study indicate that PD patients should be considered at increased risk of having dry eye problems. Schirmer’s test scores and meibomian glands are significantly affected in comparison to control cases. These results agree with previous research [3–5] and suggest that aqueous tear production is the most affected feature in PD. Some study results [2,3] suggest that PD patients have also deficits in the tear film mucin layer. In our study, TBUT did not significantly differ between PD patients and controls. Moreover, the percentage of eyes with abnormal TBUT, defined as no greater than 5 seconds, was exactly the same in our 2 investigated groups (12.2%). Also, tear film osmolarity did not significantly differ between PD and control subjects. To the best of our knowledge, no other study has investigated tear film osmolarity in PD patients; therefore, further research is needed to verify these results. All abnormalities in tear film production lead to more common ocular complaints of dry eyes (higher OSDI index) in PD patients. Moreover, symptoms of dry eye syndrome can be aggravated by seborrhoic blepharitis, which is most likely secondary to seborrhea. Researchers hypothesize that abnormalities of the tear film may be the result of autonomic dysfunction due to presence of Lewy bodies at sympathetic ganglia, substantia nigra, and peripheral parasympathetic ganglia [28], as well as decreased androgen levels [29].
We found a greater risk of primary open-angle glaucoma (16.33%) in PD patients. To date, only 1 study has reported an increased rate of glaucoma in patients with PD (23.7%) – mostly normal tension glaucoma [6]. Glaucoma in PD may be a result of decreased level of reduced glutathione (GSH), a prominent antioxidant found in the eye [30,31]. GSH protects ocular tissue from damage caused by oxidative stress, which is implicated in the pathogenesis of primary open-angle glaucoma, especially with normal IOP [32]. When compared to without glaucoma who participated in the present study, IOP turned out to be significantly lower in the PD group and the mean was within normal limits. Studies concerned with visual field changes in PD patients reported more frequent occurrence of glaucoma-like visual field defects, without any other clinical signs of glaucoma [33,34]. Tsironi et al. [33] suggested that the functional deficit observed in PD patients can be explained by intra-retinal, subcortical, and cortical neuronal disorganization or injury related to PD. Prospective longitudinal investigations of these patients would be valuable to determine repeatability or progression of glaucoma-like visual field defects. In present study, OCT examinations of peripapillary RNFL thickness did not reveal significant differences between PD patients and control cases without glaucoma. The results of previous OCT studies are inconclusive. Some studies reported RNFL thinning in PD cases [36–39], while other did not support this [21,33,40,41]. Perimacular RT also did not significantly differ between the 2 examined groups. Results of OCT studies are also inconclusive [21,36,37,40]. Also in this matter, results of OCT seems to be not useful in the PD diagnosis.
We believe the present study is the first to analyze the frequency of ARMD in PD. The neurodegenerative mechanisms of ARMD and PD were found to be quite similar and include impairment of the autophagy system, chronic inflammation, oxidative stress, and aging [42]. Moreover, dopamine seems to be involved in reduction of photoreceptor waste product accumulation [18]. However, we did not observe a significantly higher frequency of ARMD in the PD group compared to controls. Among patients with ARMD, all PD subjects had dry form, while in the control group 1 patient had neovascular form and the rest had dry form. In the literature, only 1 study [42] reported some relationship between ARMD and PD, observing that subjects with neovascular ARMD were at a significant risk of PD during a 3-year follow-up period after diagnosis. Further studies are needed to confirm these findings and explore the underlying pathomechanism.
Conclusions
Clinical examination of PD patients by general ophthalmologists requires knowledge of the common, but often underdiagnosed, ocular features of PD. Simple interventions can often significantly improve patient quality of life. PD patients should have a proper refraction to facilitate their daily activities and prevent falls. When prescribing glasses, the spherical equivalent may be preferable to significant astigmatic correction, as glasses tend not to be stable on patients with tremor or dyskinesias [2]. Early management of cataract also is important in preservation of good vision. It is important to note that chances for successful cataract surgery are better in early stages of PD when involuntary head and body movements are less advanced. Because many PD patients have decreased contrast sensitivity and color vision, good ambient light while reading is required. Convergence insufficiency should be detected and treated with reading glasses with base-in prism or monocular occlusion while reading, when required [2]. Because PD patients often complain of dry eye symptoms, artificial tears should be prescribed to provide adequate corneal lubrication. However, ophthalmologists must remember the possibility of seborrhoic blepharitis and MGD, which may require daily eyelid hygiene. PD patients should be considered as being at increased risk of primary open-angle glaucoma. The attribution of glaucomatous visual field defects with definite glaucoma, especially with the absence of elevated IOP, can be clinically challenging. In such cases, careful attention to the matching patterns of structural and functional damage is critical for assessment of possible glaucomatous damage [33]. Clinicians need to be aware of the association between PD and coexistence of ophthalmological changes, especially that restoration of good quality of vision has a great impact on the PD patients’ quality of life, and reduction of costs of treatment and care, as well as rehabilitation.
References
1. Djamgoz MB, Hankins MW, Hirano J, Archer SN, Neurobiology of retinal dopamine in relation to degenerative states of the tissue: Vision Res, 1997; 37; 3509-29, pmid: 9425527
2. Biousse V, Skibell BC, Watts RL, Ophthalmologic features of Parkinson’s disease: Neurology, 2004; 62; 177-80, pmid: 14745050
3. Tamer C, Melek IM, Duman T, Oksüz H, Tear film tests in Parkinson’s disease patients: Ophthalmology, 2005; 112; 1795, pmid: 16095705
4. Bagheri H, Berlan M, Senard JM, Lacrimation in Parkinson’s disease: Clin Neuropharmacol, 1994; 17; 89-91, pmid: 8149363
5. Kwon OY, Kim SH, Kim JH, Schrimer test in Parkinson’s disease: J Korean Med Sci, 1994; 9; 239-42, pmid: 7993591
6. Bayer AU, Keller ON, Ferrari F, Maag KP, Association of glaucoma with neurodegenerative diseases with apoptotic cell death: Alzheimer’s disease and Parkinson’s disease: Am J Ophthalmol, 2002; 133; 135-37, pmid: 11755850
7. Davidsdottir S, Cronin-Golomb A, Lee A, Visual and spatial symptoms in Parkinson’s disease: Vision Res, 2005; 45; 1285-96, pmid: 15733961
8. de Maindreville AD, Fénelon G, Mahieux F, Hallucinations in Parkinson’s disease: a follow-up study: Mov Disord, 2005; 20; 212-17, pmid: 15390044
9. Barnes J, David AS, Visual hallucinations in Parkinson’s disease: a review and phenomenological survey: J Neurol Neurosurg Psychiatry, 2001; 70; 727-33, pmid: 11385004
10. Armstrong IT, Chan F, Riopelle RJ, Munoz DP, Control of saccades in Parkinson’s disease: Brain Cogn, 2002; 49; 198-201, pmid: 15259388
11. Chan F, Armstrong IT, Pari G, Deficits in saccadic eye-movement control in Parkinson’s disease: Neuropsychologia, 2005; 43; 784-96, pmid: 15721191
12. Archibald NK, Clarke MP, Mosimann UP, Burn DJ, Visual symptoms in Parkinson’s disease and Parkinson’s disease dementia: Mov Disord, 2011; 26; 2387-95, pmid: 21953737
13. Pieri V, Diederich NJ, Raman R, Goetz CG, Decreased color discrimination and contrast sensitivity in Parkinson’s disease: J Neurol Sci, 2000; 172; 7-11, pmid: 10620653
14. Uc EY, Rizzo M, Anderson SW, Visual dysfunction in Parkinson disease without dementia: Neurology, 2005; 65; 1907-13, pmid: 16282276
15. Price MJ, Feldman RG, Adelberg D, Kayne H, Abnormalities in color vision and contrast sensitivity in Parkinson’s disease: Neurology, 1992; 42; 887-90, pmid: 1565248
16. Bron AJ, Benjamin L, Snibson GR, Meibomian gland disease. Classification and grading of lid changes: Eye (Lond), 1991; 5; 395-411, pmid: 1743355
17. Wink B, Harris J, A model of the Parkinsonian visual system: support for the dark adaptation hypothesis: Vision Res, 2000; 40; 1937-46, pmid: 10837836
18. Dubocovich ML, Role of Melatonin in Retina: Progress in Retinal Research, 1988; 129-51
19. Nguyen-Legros J, Versaux-Botteri C, Vernier P, Dopamine receptor localization in the mammalian retina: Mol Neurobiol, 1999; 19; 181-204, pmid: 10495103
20. Linden R, The anti-death league: associative control of apoptosis in developing retinal tissue: Brain Res Brain Res Rev, 2000; 32; 146-58, pmid: 10751664
21. Archibald NK, Clarke MP, Mosimann UP, Burn DJ, Retinal thickness in Parkinson’s disease: Parkinsonism Relat Disord, 2011; 17; 431-36, pmid: 21454118
22. Armstrong RA, Visual symptoms in Parkinson’s disease: Parkinsons Dis, 2011; 2011; 908306, pmid: 21687773
23. Sacca SC, Bolognesi C, Battistella A, Gene-environment interactions in ocular diseases: Mutat Res, 2009; 66; 98-117, pmid: 19046976
24. Almer Z, Klein KS, Marsh L, Ocular motor and sensory function in Parkinson’s disease: Ophthalmology, 2012; 119; 178-82, pmid: 21959370
25. Onofrj M, Bonanni L, Albani G, Visual hallucinations in Parkinson’s disease: clues to separate origins: J Neurol Sci, 2006; 248; 143-50, pmid: 16806269
26. Matsui H, Udaka F, Tamura A, Impaired visual acuity as a risk factor for visual hallucinations in Parkinson’s disease: J Geriatr Psychiatry Neurol, 2006; 19; 36-40, pmid: 16449759
27. Diederich NJ, Goetz CG, Raman R, Poor visual discrimination and visual hallucinations in Parkinson’s disease: Clin Neuropharmacol, 1998; 21; 289-95, pmid: 9789709
28. Kandel ER, Schwartz , Jessell TM: Principles of Neural Science, 1991, New York, Elsevier
29. Okun MS, McDonald WM, DeLong MR, Refractory nonmotor symptoms in male patients with Parkinson disease due to testosterone deficiency: a common unrecognized comorbidity: Arch Neurol, 2002; 59; 807-11, pmid: 12020264
30. Costarides AP, Riley MV, Green K, Roles of catalase and the glutathione redox cycle in the regulation of anterior-chamber hydrogen peroxide: Ophthalmic Res, 1991; 23; 284-94, pmid: 1784460
31. Perry TL, Godin DV, Hansen S, Parkinson’s disease: a disorder due to nigral glutathione deficiency?: Neurosci Lett, 1982; 33; 305-10, pmid: 7162692
32. Njie-Mbye YF, Kulkarni-Chitnis M, Opere CA, Lipid peroxidation: pathophysiological and pharmacological implications in the eye: Front Physiol, 2013; 4; 366, pmid: 24379787
33. Tsironi EE, Dastiridou A, Katsanos A, Perimetric and retinal nerve fiber layer findings in patients with Parkinson’s disease: BMC Ophthalmol, 2012; 12; 54, pmid: 23031247
34. Yenice O, Onal S, Midi I, Visual field analysis in patients with Parkinson’s disease: Parkinsonism Relat Disord, 2008; 14; 193-98, pmid: 17888714
35. McKinnon SJ, Glaucoma, apoptosis, and neuroprotection: Curr Opin Ophthalmol, 1997; 8; 28-37, pmid: 10168354
36. Garcia-Martin E, Rodriguez-Mena D, Satue M, Electrophysiology and optical coherence tomography to evaluate Parkinson disease severity: Invest Ophthalmol Vis Sci, 2014; 55; 696-705, pmid: 24425856
37. Satue M, Seral M, Otin S, Retinal thinning and correlation with functional disability in patients with Parkinson’s disease: Br J Ophthalmol, 2014; 98; 350-55, pmid: 24276697
38. Altinaş O, Iseri PK, Tokay T, Yüksel N, Relationship between cognitive impairment and retinal morphological and visual functional abnormalities in Alzheimer disease: J Neuroophthalmol, 2006; 26; 18-24, pmid: 16518161
39. Inzelberg R, Ramirez JA, Nisipeanu P, Ophir A, Retinal nerve fiber layer thinning in Parkinson disease: Vision Res, 2004; 44; 2793-97, pmid: 15342223
40. Albrecht P, Müller AK, Südmeyer M, Optical coherence tomography in parkinsonian syndromes: PLoS One, 2012; 7; e34891, pmid: 22514688
41. Aaker GD, Myung JS, Ehrlich JR, Detection of retinal changes in Parkinson’s disease with spectral-domain optical coherence tomography: Clin Ophthalmol, 2010; 4; 1427-32, pmid: 21188154
42. Chung SD, Ho JD, Hu CC, Increased risk of Parkinson disease following a diagnosis of neovascular age-related macular degeneration: a retrospective cohort study: Am J Ophthalmol, 2014; 157; 464-69, pmid: 24315292
In Press
Clinical Research
Institutional and Regional Variations in Access to Clinical Trials and Next-Generation Sequencing in Turkis...Med Sci Monit In Press; DOI: 10.12659/MSM.951027
Clinical Research
Low-Intensity Blood Flow-Restricted Multi-Joint Exercise Improves Muscle Function in Patients With Patellof...Med Sci Monit In Press; DOI: 10.12659/MSM.950516
Review article
Musculoskeletal Ultrasound and MRI in the Evaluation of Chemotherapy-Induced Peripheral Neuropathy: A ReviewMed Sci Monit In Press; DOI: 10.12659/MSM.951283
Clinical Research
Sensory Processing, Dissociation, and Affective Symptoms in Misophonia: A Cross-Sectional Study of 35 AdultsMed Sci Monit In Press; DOI: 10.12659/MSM.950938
Most Viewed Current Articles
17 Jan 2024 : Review article 10,187,196
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
13 Nov 2021 : Clinical Research 3,708,487
Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...DOI :10.12659/MSM.932788
Med Sci Monit 2021; 27:e932788
14 Dec 2022 : Clinical Research 2,341,643
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research 706,524
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387






